Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
The Patient|August 11, 2023
Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UKJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 1, 2019
Management algorithms for metastatic prostate cancerShawn Malone, Bobby Shayegan, Naveen S Basappa, et al.
Cancer Letters|April 26, 2026
Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate CancerAmr Ali, Fiorella Di Pastena, Olga-Demetra Biziotis, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
American Journal of Clinical Oncology|January 1, 2010
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancerSrikala S Sridhar, Sebastien J Hotte, Joseph L Chin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancerEric K Nguyen, Hang Yu, Gregory Pond, et al.
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
The Patient|August 11, 2023
Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UKJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 1, 2019
Management algorithms for metastatic prostate cancerShawn Malone, Bobby Shayegan, Naveen S Basappa, et al.
Cancer Letters|April 26, 2026
Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate CancerAmr Ali, Fiorella Di Pastena, Olga-Demetra Biziotis, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
American Journal of Clinical Oncology|January 1, 2010
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancerSrikala S Sridhar, Sebastien J Hotte, Joseph L Chin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancerEric K Nguyen, Hang Yu, Gregory Pond, et al.
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Pageof 9